SuperworthGyre Therapeutics EPS GYRE
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- −$0.21
- Latest quarter, Q2 FY26
- −$0.12
- Fiscal year 2025
- −$0.02
- −140% on the year before
Gyre Therapeutics' earnings per share was −$0.21 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.12.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.02 | −140% |
| FY2024 | $0.05 | n/a |
| FY2023 | −$1.29 | n/a |
| FY2022 | −$3.75 | n/a |
| FY2021 | −$43.20 | n/a |
| FY2020 | −$42.45 | n/a |
| FY2019 | −$69.00 | n/a |
| FY2018 | −$39.75 | n/a |
| FY2017 | −$145.50 | n/a |
| FY2016 | −$326.40 | n/a |
| FY2015 | −$3071.25 | n/a |
| FY2014 | −$4054.50 | n/a |
| FY2013 | −$2189.25 | n/a |
| FY2012 | −$330.75 | n/a |
| FY2011 | −$346.50 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.12 | n/a | −$0.21 | |
| Q1 FY26 | −$0.10 | n/a | −$0.12 | |
| Q4 FY25 | −$0.02 | n/a | −$0.02 | |
| Q3 FY25 | $0.03 | +200% | $0.00 | |
| Q2 FY25 | −$0.03 | −400% | −$0.02 | |
| Q1 FY25 | $0.00 | −100% | $0.02 | |
| Q4 FY24 | $0.00 | n/a | $0.05 | |
| Q3 FY24 | $0.01 | −80% | −$1.34 | |
| Q2 FY24 | $0.01 | −50% | −$1.30 | |
| Q1 FY24 | $0.03 | +0% | −$1.29 | |
| Q4 FY23 | −$1.39 | n/a | −$1.29 | |
| Q3 FY23 | $0.05 | n/a | −$18.95 |
Against its peers
Companies in Drug Manufacturers - General nearest Gyre Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| GYREGyre Therapeutics | −$0.21 | |
| CRMDCorMedix | $2.13 | +184% a year |
| ZVRAZevra Therapeutics | $0.93 | |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| ABUSArbutus Biopharma | $0.78 | |
| ARVNArvinas | $0.16 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| OMEROmeros | $1.52 | |
| PCRXPacira BioSciences | $0.35 | |
| Peer median | $0.85 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Gyre Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.